| human | Q5 |
| P496 | ORCID iD | 0000-0003-4826-5430 |
| P69 | educated at | Minnesota State University, Mankato | Q1937387 |
| Nicolae Testemițanu State University of Medicine and Pharmacy | Q4146986 | ||
| P108 | employer | Minnesota State University, Mankato | Q1937387 |
| Mayo Clinic | Q1130172 | ||
| P735 | given name | Marina | Q1120708 |
| Marina | Q1120708 | ||
| P106 | occupation | researcher | Q1650915 |
| Q100696114 | Association of amyloid angiopathy with microbleeds in logopenic progressive aphasia: an imaging-pathology study |
| Q92587499 | Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes |
| Q104067076 | Lewy body disease is a contributor to logopenic progressive aphasia phenotype |
| Q91953658 | MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous |
| Q112576092 | Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition |
| Q114888854 | Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease |
| Q101324621 | Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy |
| Q99637905 | Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration |
| Q89476365 | TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease |
| Q96229271 | Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy |
Search more.